Short Interest in VBI Vaccines Inc. (NASDAQ:VBIV) Declines By 33.6%

VBI Vaccines Inc. (NASDAQ:VBIV) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 276,900 shares, a drop of 33.6% from the June 30th total of 417,000 shares. Based on an average daily volume of 153,200 shares, the short-interest ratio is currently 1.8 days. Approximately 1.1% of the shares of the company are short sold.

VBI Vaccines Stock Performance

NASDAQ VBIV traded up $0.02 during midday trading on Friday, hitting $0.56. The company had a trading volume of 95,521 shares, compared to its average volume of 186,968. The firm has a fifty day simple moving average of $0.65 and a two-hundred day simple moving average of $0.63. VBI Vaccines has a fifty-two week low of $0.45 and a fifty-two week high of $1.36.

VBI Vaccines (NASDAQ:VBIV) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.85 million. Equities research analysts forecast that VBI Vaccines will post -1.23 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of VBI Vaccines in a research report on Tuesday. They issued a “sell” rating on the stock.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.